Improving Patient Outcome with Early Detection of HCC
Schedule Telemedicine Consult with Dr. Gish Powered byTelemed2U
Powered byTelemed2U

Improving Patient Outcome with Early Detection of HCC

Information of HCC biomarkers, AFP-L3, AFP and DCP (same as PIVKA II) assays on uTASWako i30 automated analyzer. As you can see, AFP-L3 and/or DCP elevated more than cut-off values and earlier than AFP. Therefore, AFP-L3 and DCP are more specific biomarkers for early stage of HCC and the combination use of these three biomarkers detect more HCCs.

View Document


Paving a New Frontier in Clinical Chemistry


Information of the uTASWako i30 immunoassay system using microfluidic chip technology. Easy to use and first results in 9 min after you push the start button and subsequent results every two minutes.

View Document


Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients

HCC model using three HCC biomarkers. Dr. Philip Johnson in the UK and our WAKO collaborated to develop the model. This model provides better performance for HCC diagnosis and prognosis compared to individual biomarkers.

GALAD Calculator

View Document


Article Metadata